An association between erythropoietin treatment and increased mortality was originally suggested by two studies in cancer patients (Henke et al, 2003; Leyland-Jones et al, 2005) raising concerns about the safety of ESAs when targeting high Hb levels (12–14 g dl−1 or higher) (Luksenburg et al, 2004). Here, GSTM1 is linked to cancer.